Upadatinib launch time and price in China: latest purchasing channels in 2025

Upadacitinib (Upadacitinib) has quickly attracted attention in the domestic medical community since it was approved for marketing by the National Medical Products Administration in 2022. The drug was initially approved in Europe and the United States for the treatment of diseases such as rheumatoid arthritis, psoriatic arthritis and ulcerative colitis, and is priority used in China to treat patients with rheumatoid arthritis and psoriasis, especially those who have failed treatment with traditional DMARDs or TNF inhibitors.

In China, the common dosage form of upadatinib is15 mg oral tablets, 28 tablets per box. According to the current procurement quotations from mainstream pharmacies and hospitals, the price of original drugs ranges from approximately RMB 2,000 to RMB 2,500, which may vary slightly depending on the region, the degree of inclusion in the medical insurance directory, and the hospital’s procurement channels. It is worth noting that upatinib has been included in China’s national medical insurance directory, which has played a key role in reducing patients’ financial burden. After actual reimbursement, the out-of-pocket portion has dropped significantly.

In overseas markets, such as the EU version or the United StatesThe original drug approved by the FDA is more expensive, about RMB 20,000 per box, and the price is greatly affected by exchange rates and import tax policies. Some patients will also obtain original drugs through cross-border medical channels or purchasing agents. In addition, some economical versions of generic drugs have also begun to enter the market, such as the generic version of Upadacitinib produced by Lucius Pharmaceuticals in Laos. The active ingredients are basically the same as the original drugs and meet the consistency evaluation standards for generic drugs. The price of this version is about 500 yuan per box, which is currently an alternative choice for many patients with limited financial conditions.

In terms of legal purchase channels, patients can obtain upadatinib drugs through hospital prescriptions, pharmacies, cross-border e-commerce platforms or international medical hotlines. When choosing a purchasing channel, priority should be given to formal and traceable platforms to avoid affecting efficacy or safety due to unknown drug quality or improper storage and transportation.

Reference materials:https://www.rinvoq.com/